MEI Pharma, Inc. (MEIP): Price and Financial Metrics

MEI Pharma, Inc. (MEIP): $0.25

0.01 (+3.90%)

POWR Rating

Component Grades













MEIP Stock Summary

  • MEIP has a market capitalization of $31,982,608 -- more than approximately just 11.5% of US stocks.
  • Of note is the ratio of MEI PHARMA INC's sales and general administrative expense to its total operating expenses; merely 12.67% of US stocks have a lower such ratio.
  • In terms of volatility of its share price, MEIP is more volatile than 86.12% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to MEI PHARMA INC, a group of peers worth examining would be PULM, OGEN, GSIT, PRQR, and EIGR.
  • MEIP's SEC filings can be seen here. And to visit MEI PHARMA INC's official web site, go to

MEIP Valuation Summary

  • MEIP's EV/EBIT ratio is 2.5; this is 61.83% lower than that of the median Healthcare stock.
  • Over the past 234 months, MEIP's EV/EBIT ratio has gone up 86.7.

Below are key valuation metrics over time for MEIP.

Stock Date P/S P/B P/E EV/EBIT
MEIP 2023-03-17 0.5 0.7 -1.0 2.5
MEIP 2023-03-16 0.5 0.7 -1.1 2.5
MEIP 2023-03-15 0.5 0.7 -1.1 2.5
MEIP 2023-03-14 0.5 0.7 -1.1 2.5
MEIP 2023-03-13 0.5 0.7 -1.1 2.5
MEIP 2023-03-10 0.5 0.6 -1.0 2.6

MEIP Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at -1462.91%.
  • Its 3 year net cashflow from operations growth rate is now at -77.22%.
  • Its year over year net cashflow from operations growth rate is now at -191.93%.
Over the past 34 months, MEIP's revenue has gone up $58,034,000.

The table below shows MEIP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 62.573 -61.511 -31.159
2022-09-30 41.67 -55.807 -53.568
2022-06-30 40.697 -48.746 -54.454
2022-03-31 36.737 -44.499 -46.769
2021-12-31 44.143 -43.19 -54.675
2021-09-30 35.088 -30.574 -60.363

MEIP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MEIP has a Quality Grade of C, ranking ahead of 61.23% of graded US stocks.
  • MEIP's asset turnover comes in at 0.131 -- ranking 236th of 682 Pharmaceutical Products stocks.
  • BLUE, BPMC, and NERV are the stocks whose asset turnover ratios are most correlated with MEIP.

The table below shows MEIP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.131 0.945 -34.832
2021-03-31 0.201 0.954 -23.189
2020-12-31 0.220 0.941 -19.061
2020-09-30 0.201 0.921 -34.437
2020-06-30 0.240 0.908 10.741
2020-03-31 0.051 0.275 3.585

MEIP Price Target

For more insight on analysts targets of MEIP, see our MEIP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.67 Average Broker Recommendation 1.39 (Strong Buy)

MEIP Stock Price Chart Interactive Chart >

Price chart for MEIP

MEIP Price/Volume Stats

Current price $0.25 52-week high $1.87
Prev. close $0.24 52-week low $0.20
Day low $0.24 Volume 741,062
Day high $0.25 Avg. volume 1,136,227
50-day MA $0.29 Dividend yield N/A
200-day MA $0.40 Market Cap 33.34M

MEI Pharma, Inc. (MEIP) Company Bio

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company was founded in 2000 and is based in San Diego, California.

MEIP Latest News Stream

Event/Time News Detail
Loading, please wait...

MEIP Latest Social Stream

Loading social stream, please wait...

View Full MEIP Social Stream

Latest MEIP News From Around the Web

Below are the latest news stories about MEI PHARMA INC that investors may wish to consider to help them evaluate MEIP as an investment opportunity.

Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge

MEI Pharma Inc (NASDAQ: MEIP) and Infinity Pharmaceuticals Inc (NASDAQ: INFI) have entered into a definitive merger agreement for an all-stock transaction forming a company focusing on three clinical-stage oncology drug candidates. Infinity's Eganelisib is planned to be evaluated in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in patients with head and neck squamous cell carcinoma (HNSCC). Related: Infinity Pharma Posts 52% Increase In One-Year Progression-Free Survival R

Yahoo | February 23, 2023

MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

SAN DIEGO, CA. & CAMBRIDGE, Mass., February 23, 2023--MEI Pharma, Inc. (Nasdaq: MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies entered into a definitive merger agreement for an all-stock transaction form

Yahoo | February 23, 2023

Rainbows and Unicorns: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Just Became A Lot More Optimistic

Shareholders in MEI Pharma, Inc. ( NASDAQ:MEIP ) may be thrilled to learn that the analysts have just delivered a major...

Yahoo | February 17, 2023

MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 9, 2023

MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights

SAN DIEGO, February 09, 2023--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2022, and highlighted recent corporate events.

Yahoo | February 9, 2023

Read More 'MEIP' Stories Here

MEIP Price Returns

1-mo -21.88%
3-mo 2.04%
6-mo -40.60%
1-year -86.11%
3-year -76.42%
5-year -88.37%
YTD 2.63%
2022 -90.88%
2021 1.14%
2020 6.45%
2019 -6.06%
2018 25.71%

Continue Researching MEIP

Want to see what other sources are saying about MEI Pharma Inc's financials and stock price? Try the links below:

MEI Pharma Inc (MEIP) Stock Price | Nasdaq
MEI Pharma Inc (MEIP) Stock Quote, History and News - Yahoo Finance
MEI Pharma Inc (MEIP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.842 seconds.